Quantum dots have drawn tremendous attention in the field of in vitro and small animal in vivo fluorescence imaging in the last decade. However, concerns over the cytotoxicity of their heavy metal constituents have limited their use in clinical applications. Here, we report our comparative studies on the toxicities of quantum dots (QDs) and silica coated CdTe nanoparticles (NPs) to mice after intravenous injection. The blood cells analysis showed significant increased level of white blood cells (WBCs) in groups treated with CdTe QDs as compared to the control while red blood cells (RBCs) and platelet counts were normal in treated as well as control groups. The concentration of biochemical markers of hepatic damage, alanine amino transferase (ALT) and aspartate aminotransferase (AST) were in the normal range in all the groups. However, renal function analyses of mice showed significantly increased in the concentration of blood urea nitrogen (BUN) and creatinine (CREA) in mice treated with CdTe QDs while remained within normal ranges in both the CdTe@SiO2 NPs and control group. The results of histopathology showed that the CdTe QDs caused mild nephrotoxicity while other organs were normal and no abnormalities were detected in control and CdTe@SiO2 treated group. These findings suggest that the nephrotoxicity could be minimized by silica coating which would be useful for many biomedical applications.

A new and simple procedure to enhance the fluorescence of analytes on the surfaces of a solid substrate is demonstrated based on Ag@SiO(2) nanoparticles. Two kinds of silver-silica core-shell nanoparticles with shell thicknesses of around 3 and 15 nm have been prepared and used as enhancing agents, respectively. By simply pipetting drops of the enhancing agents onto substrate surfaces with Rose Bengal monolayers, an enhancement of about 27 times, compared with the control sample, is achieved by using the Ag@SiO(2) nanoparticles with shells of about 3 nm, whereas an enhancement of around 11.7 times is obtained when using those with thicker shells. The effects of shell thickness and surface density of the enhancing agents on the enhancement have been investigated experimentally. The results show that this method can be potentially helpful in fluorescence-based surface analysis.

No abstract

A novel gap-plasmon-tunable Ag bilayer nanoparticle film for immunoassays is demonstrated. Different from a traditional Ag monolayer nanoparticle film, a desired number of polyelectrolyte (PEL) layers are deposited on the nanoparticles before the self-assembly of a second Ag nanoparticle layer. Interestingly, by controlling the number of the PEL interlayers, the gap plasmon between the two Ag nanoparticle layers can be tuned across the visible spectral range. The ability of the presented Ag bilayer nanoparticle films in fluorescence enhancement has been examined experimentally. A maximal enhancement of around 15.4 fold was achieved when 7 layers of polyelectrolyte were used. When this optimal Ag bilayer nanoparticle film was applied to fluorescence immunoassay, a performance with approximately 3.3-fold enhancement was obtained compared with that performed on a traditional glass substrate. The experimental results suggest that the presented gap-plasmon tunable Ag bilayer nanoparticle films have great potential in fluorescence-based immunoassays. The method of the bilayer-film construction presented here also provides new insights into the rational design of the plasmonic substrates.

Background: Many of the tropical diseases are neglected by the researchers and medicinal companies due to lack of profit and other interests. The Drugs for Neglected Diseases initiative (DNDi) is established to overcome the problems associated with these neglected diseases. According to a report published by the WHO, leprosy (Hansen's disease) is also a neglected infectious disease. Methods: A negligible amount of advancements has been made in last few decades which includes the tools of diagnosis, causes, treatment, and genetic studies of the bacterium (Mycobacterium leprae) that causes leprosy. The diagnosis of leprosy at earlier stages is important for its effective treatment. Recent studies on vitamin D and its receptors make leprosy diagnosis easier at earlier stages. Skin biopsies and qPCR are the other tools to identify the disease at its initial stages. Results: Until now a specific drug for the treatment of leprosy is not available, therefore, Multi-Drug Therapy (MDT) is used, which is hazardous to health. Besides Mycobacterium leprae, recently a new bacterium Mycobacterium lepromatosis was also identified as a cause of leprosy. During the last few years the genetic studies of Mycobacterium leprae, the role of vitamin D and vitamin D receptors (VDR), and the skin biopsies made the treatment and diagnosis of leprosy easier at early stages. The studies of micro RNAs (miRNAs) made it easy to differentiate leprosy from other diseases especially from tuberculosis. Conclusion: Leprosy can be distinguished from sarcoidosis by quantitative study of reticulin fibers present in skin. The treatment used until now for leprosy is multi-drug treatment. The complete genome identification of Mycobacterium leprae makes the research easy to develop target specified drugs for leprosy. Rifampicin, identified as a potent drug, along with other drugs in uniform multi-drug treatment, has a significant effect when given to leprosy patients at initial stages. These are effective treatments but a specific drug for leprosy is still needed to be identified. The current review highlights the use of modern methods for the identification of leprosy at its earlier stages and the effective use of drugs alone as well as in combination.